Transcept Pharma (TSPT) surges on agreement news
Shares of Transcept Pharmaceuticals (NASDAQ: TSPT) surged 43% to $8.30 Monday, as the company and Purdue Pharmaceutical Products announced that they have entered into an exclusive license and collaboration agreement to commercialize prescription sleep aid drug Intermezzo in the United States.
Response Biomedical (RBM) gets FDA clearance on virus test
In breaking news Wednesday, Vancouver-based Response Biomedical Corporation (TSX: T.RBM) announced that it received a U.S. FDA 510(k) clearance to market a rapid Respiratory Syncytial Virus test.
Labopharm (DDS) shares down on FDA news
Shares of Quebec-based Labopharm (TSX: T.DDS) fell more than 13% to $2.06 Monday, as the company says the U.S. FDA will not approve its application for the antidepressant Trazodone in its present form as a result of deficiencies at a manufacturing facility.
Pharma firm’s shares jump on FDA approval news
Shares of Angiotech Pharmaceuticals (TSX: T.ANP) surged 29% to $2.09 Thursday, as the Vancouver-based company reported that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received U.S. FDA approval to market its TAXUS Liberté Long Paclitaxel-Eluting Coronary Stent System, a drug-eluting stent designed for long lesions.
Nuvo climbs on agreement news
Shares of Ontario-based drug development firm Nuvo Research (TSX: T.NRI) climbed 9.7% to 39.5 cents Tuesday, after the company announced that it has entered into a license and development agreement with subsidiary of Covidien
IDM Pharma surges on acquisition news
Shares of California-based IDM Pharma (NASDAQ: IDMI) soared 53.5% to $2.61 Monday, after the company announced that Japan’s Takeda Pharmaceutical Company’s subsidiary, Takeda America Holdings, Inc., will acquire IDM for US$2.64 per share in an all cash tender offer followed by a merger.
Orbus Pharma jumps as Health Canada approves product sale
Shares of Ontario-based Orbus Pharma (TSX: T.ORB) jumped 75% to 10.5 cents Friday, after the company announced after Thursday’s market close that generic pharmaceutical company ratiopharm has received a Notice of Compliance from Health Canada approving the sale of a generic form of the anti-depressant Amitriptyline in Canada.
Paladin Labs reports Q1 results, strategic partnership
Montreal-based specialty pharmaceutical firm Paladin Labs (TSX: T.PLB) reported its 2009 first quarter financial results Thursday, as well as news of a strategic partnership with a biopharmaceutical company.
Latest Ticker Trax Report Reveals Fair Value of BioCryst Pharmaceuticals Inc. (BCRX)
Today Stockhouse.com announced the release of its newest issue of Ticker Trax, an investment report written by Thom Calandra. This report reveals a special focus on BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), a developer of the anti-viral peramivir, which was identified in December 2008 as a ‘Top Portfolio Prospect’ for subscribers in the life sciences component of the Ticker Trax portfolio. The recent influenza outbreaks saw shares of BioCryst gain nearly 140% this week alone, leaving many wondering what’s next for this dynamic stock.
